Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/173863
Title: Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome in Spain: Clinical and Genetic Characterization
Author: Sánchez Heras, Ana Beatriz
Castillejo, Adela
García Díaz, Juan de Dios
Robledo, Mercedes
Teulé-Vega, Àlex
Sánchez, Rosario
Zúñiga, Ángel
Lastra, Enrique
Durán, Mercedes
Llort, Gemma
Yagüe, Carmen
Ramón y Cajal, Teresa
López San Martín, Consol
López Fernández, Adrià
Balmaña, Judith
Robles, Luis
Mesa Latorre, José M.
Chirivella González, Isabel
Fonfria, María
Perea Ibañez, Raquel
Castillejo, M. Isabel
Escandell, Inés
Gomez, Luis
Berbel, Pere
Soto, Jose Luis
Keywords: Malalties rares
Malalties hereditàries
Cèl·lules canceroses
Malalties del ronyó
Rare diseases
Genetic disorders
Cancer cells
Kidney diseases
Issue Date: 1-Nov-2020
Publisher: Mdpi
Abstract: Simple Summary Hereditary leiomyomatosis and renal cell cancer (HLRCC) syndrome is a very rare hereditary disorder characterized by cutaneous leiomyomas (CLMs), uterine leiomyomas (ULMs), renal cysts (RCys) and renal cell cancer (RCC), with no data on its prevalence worldwide. No genotype-phenotype associations have been described. The aim of our study was to describe the genotypic and phenotypic features of the largest series of patients with HLRCC from Spain reported to date. Of 27 FH germline pathogenic variants, 12 were not previously reported in databases. Patients with missense pathogenic variants showed higher frequencies of CLMs, ULMs and RCys, than those with loss-of-function variants. The frequency of RCCs (10.9%) was lower than those reported in the previously published series. Hereditary leiomyomatosis and renal cell cancer syndrome (HLRCC) is a very rare hereditary disorder characterized by cutaneous leiomyomas (CLMs), uterine leiomyomas (ULMs), renal cysts (RCys) and renal cell cancers (RCCs). We aimed to describe the genetics, clinical features and potential genotype-phenotype associations in the largest cohort of fumarate hydratase enzyme mutation carriers known from Spain using a multicentre, retrospective study of individuals with a genetic or clinical diagnosis of HLRCC. We collected clinical information from medical records, analysed genetic variants and looked for genotype-phenotype associations. Analyses were performed using R 3.6.0. software. We included 197 individuals: 74 index cases and 123 relatives. CLMs were diagnosed in 65% of patients, ULMs in 90% of women, RCys in 37% and RCC in 10.9%. Twenty-seven different pathogenic variants were detected, 12 (44%) of them not reported previously. Patients with missense pathogenic variants showed higher frequencies of CLMs, ULMs and RCys, than those with loss-of-function variants (p = 0.0380, p = 0.0015 and p = 0.024, respectively). This is the first report of patients with HLRCC from Spain. The frequency of RCCs was lower than those reported in the previously published series. Individuals with missense pathogenic variants had higher frequencies of CLMs, ULMs and RCys.
Note: Reproducció del document publicat a: https://doi.org/10.3390/cancers12113277
It is part of: Cancers, 2020, Vol. 12(11), num. 3277
URI: http://hdl.handle.net/2445/173863
Related resource: https://doi.org/10.3390/cancers12113277
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
Sanchez-HerasAB.pdf1.18 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons